MART-1 (26-35) (human) is amino acid residue 26 to 35 of MART-1 protein.

MART-1 (Melan-A) gene is 18 kb long and comprises five exons. It is expressed in most melanoma tumor samples, and among normal cells, only in melanocytes^[1]. In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. The epitopes spanning amino acid residues 26–35 and 27–35 from the MART-1/Melan-A protein, highly expressed in melanoma cells, provide a prime example of T cell recognition of multiple peptides and the use of peptide variants designed to elicit altered immunological responses^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

943.10

C₄₂H₇₄N₁₀O₁₄

156251-01-3

Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val

EAAGIGILTV

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

3.;;Recommended solution:

• [1]. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994 Jul 1;180(1):35-42.

  [2]. Borbulevych OY, et al. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol. 2007 Oct 5;372(5):1123-36.

MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.

MART-1 (Melan-A) gene is 18 kb long and comprises five exons. It is expressed in most melanoma tumor samples, and among normal cells, only in melanocytes ^[1] . In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. The epitopes spanning amino acid residues 26–35 and 27–35 from the MART-1/Melan-A protein, highly expressed in melanoma cells, provide a prime example of T cell recognition of multiple peptides and the use of peptide variants designed to elicit altered immunological responses ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1057.12

C₄₄H₇₅F₃N₁₀O₁₆

Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val

EAAGIGILTV

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

H₂O : 5 mg/mL (4.73 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

• [1]. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994 Jul 1;180(1):35-42.

  [2]. Borbulevych OY, et al. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol. 2007 Oct 5;372(5):1123-36.